Chanita Hughes-Halbert named associate director for cancer equity at USC Norris

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Chanita Hughes-Halbert was named director for cancer equity at University of Southern California Norris Comprehensive Cancer Center, and professor and vice chair of research in the Department of Preventive Medicine at Keck School of Medicine. 

Her appointment begins July 1, 2021.

Hughes-Halbert will join USC from the Medical University of South Carolina, where she is a professor of psychiatry and behavioral sciences, co-leader of the Cancer Control Program, holder of the AT&T Distinguished Endowed Chair at the Hollings Cancer Center and associate dean for assessment, evaluation and quality improvement at the College of Medicine.

Her work is focused on reducing the disparities in cancer outcomes that affect patients from underrepresented communities, with a primary focus on African American communities.

Hughes-Halbert has identified sociocultural, psychological, genetic and environmental determinants of cancer health disparities and translates this information into interventions to improve health equity among racially and ethnically diverse populations, as well as other medically underserved groups. 

Hughes-Halbert was elected to the National Academy of Medicine in 2017. 

At her current post, Hughes-Halbert directs the Transdisciplinary Collaborative Center in Precision Medicine and Minority Men’s Health. This program aims to develop medical strategies for minority men that are tailored to the specific social, genetic and environmental factors affecting each person’s health, with a focus on cancer.

President Barack Obama appointed Hughes-Halbert to NCI’s Board of Scientific Advisors in 2012, and in 2014 she joined the National Advisory Council of the National Human Genome Research Institute. 

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login